华神科技,000790,收入构成,报告日期,2021-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 中西成药,24145,7174,16971,70.29%,96.45% 生物制药,400,81,319,79.74%,1.81% 其他,497,-- ,-- ,--,0% 钢结构制作安装服务,8450,8143,307,3.63%,1.74% 华神科技,000790,收入构成,报告日期,2020-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 中西成药,56113,15665,40448,72.08%,98.42% 生物制药,440,421,19,4.4%,0.05% 其他,1562,507,1055,67.55%,2.57% 钢结构制作安装服务,17815,18238,-423,-2.38%,-1.03% 华神科技,000790,收入构成,报告日期,2020-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 中西成药,25079,6786,18293,72.94%,96.82% 生物制药,154,311,-157,-101.58%,-0.83% 其他(补充),541,214,327,60.43%,1.73% 钢结构制作安装服务,5453,5022,431,7.91%,2.28% 华神科技,000790,收入构成,报告日期,2019-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,1265,-- ,-- ,--,0% 中西成药,64082,17344,46738,72.93%,101.61% 生物制药,716,-- ,-- ,--,0% 钢结构制作安装服务,8472,9212,-740,-8.73%,-1.61% 华神科技,000790,收入构成,报告日期,2019-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 钢结构制作安装服务,1328,1257,71,5.38%,0.3% 其他(补充),600,218,382,63.64%,1.61% 生物制药,359,392,-33,-9.14%,-0.14% 中西成药,31953,8606,23347,73.07%,98.23% 华神科技,000790,收入构成,报告日期,2018-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 中西成药,58456,16517,41938,71.74%,101.29% 其他(补充),848,519,330,38.86%,0.8% 生物制药,594,1085,-491,-82.56%,-1.19% 钢结构制作安装服务,3443,3818,-375,-10.88%,-0.9% 华神科技,000790,收入构成,报告日期,2018-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 生物制药,218,478,-261,-119.89%,-1.51% 其他(补充),350,162,188,53.74%,1.09% 钢结构制作安装服务,1072,1023,49,4.56%,0.28% 中西成药,24738,7410,17328,70.05%,100.14% 华神科技,000790,收入构成,报告日期,2017-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),315,88,227,71.98%,0.73% 钢结构制作安装服务,8250,7666,584,7.07%,1.88% 生物制药,736,1037,-301,-40.87%,-0.97% 中西成药,49793,19202,30591,61.44%,98.36% 华神科技,000790,收入构成,报告日期,2017-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 生物制药,448,478,-30,-6.68%,-0.24% 中西成药,20253,8494,11760,58.06%,94.38% 其他(补充),70,27,43,61.67%,0.35% 钢结构设计制作安装服务,5290,4603,687,12.99%,5.51% 华神科技,000790,收入构成,报告日期,2016-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,933,327,606,64.93%,1.92% 钢结构制作安装服务,11669,10110,1558,13.35%,4.95% 生物制药,1068,1574,-505,-47.32%,-1.61% 中西成药,43849,14021,29829,68.03%,94.73% 华神科技,000790,收入构成,报告日期,2016-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),566,153,413,73.03%,2.89% 钢结构设计制作安装服务,2771,2406,364,13.15%,2.55% 生物制药,609,863,-254,-41.7%,-1.77% 中西成药,20158,6377,13781,68.36%,96.34% 华神科技,000790,收入构成,报告日期,2015-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,855,321,534,62.47%,2.15% 建筑钢结构,6761,7341,-579,-8.57%,-2.33% 生物制药,1021,602,420,41.11%,1.69% 中西成药,37694,13211,24483,64.95%,98.49% 华神科技,000790,收入构成,报告日期,2015-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 生物制药,542,235,307,56.61%,2.5% 其他(补充),498,170,328,65.88%,2.67% 钢结构设计制作安装服务,4449,4379,70,1.57%,0.57% 中西成药,19037,7471,11566,60.75%,94.26% 华神科技,000790,收入构成,报告日期,2014-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),784,347,437,55.77%,1.9% 生物制药,1253,529,723,57.75%,3.15% 中西成药,35164,13868,21296,60.56%,92.59% 钢结构设计制作安装服务,15621,15077,544,3.48%,2.36% 华神科技,000790,收入构成,报告日期,2014-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),454,-- ,-- ,--,0% 钢结构设计制作安装服务,7891,7645,246,3.11%,2.02% 生物制药(利卡汀),663,271,392,59.16%,3.23% 中西成药,18372,6847,11524,62.73%,94.75% 华神科技,000790,收入构成,报告日期,2013-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),716,302,414,57.78%,1.76% 兽药及兽用生物疫苗,-- ,-- ,-- ,--,0% 钢结构设计制作安装服务,32527,28409,4119,12.66%,17.52% 生物制药,1959,620,1339,68.33%,5.69% 中西成药,30578,12940,17638,57.68%,75.03% 华神科技,000790,收入构成,报告日期,2013-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),394,-- ,-- ,--,0% 兽药及兽用生物疫苗,-- ,-- ,-- ,--,0% 生物制药,958,334,624,65.13%,6.05% 中西成药,13885,6005,7880,56.75%,76.41% 钢结构设计制作安装服务,13719,11910,1809,13.19%,17.54% 华神科技,000790,收入构成,报告日期,2012-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),553,279,274,49.6%,1.25% 兽药及兽用生物疫苗,42,55,-12,-28.46%,-0.06% 生物制药,2289,738,1552,67.78%,7.09% 中西成药,25656,10947,14709,57.33%,67.21% 钢结构设计制作安装服务,29512,24150,5362,18.17%,24.5% 华神科技,000790,收入构成,报告日期,2012-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 兽药及兽用生物疫苗,42,55,-12,-28.46%,-0.13% 中西成药,11673,5002,6672,57.15%,74.32% 其他(补充),320,-- ,-- ,--,0% 钢结构设计制作安装服务,11336,9679,1656,14.61%,18.45% 生物制药,999,338,662,66.2%,7.37% 华神科技,000790,收入构成,报告日期,2011-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),464,316,148,31.84%,0.84% 兽药及兽用生物疫苗,3312,2329,983,29.67%,5.6% 生物制药,2108,707,1401,66.48%,7.99% 中西成药,19738,8801,10937,55.41%,62.36% 钢结构设计制作安装服务,29529,25458,4070,13.78%,23.21% 华神科技,000790,收入构成,报告日期,2011-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),261,134,127,48.66%,1.55% 钢结构设计,-- ,-- ,-- ,--,0% 兽药及兽用生物制药,1603,1183,420,26.22%,5.13% 生物制药,786,300,486,61.84%,5.94% 其他中西成药,708,486,222,31.4%,2.71% 三七通舒胶囊,5898,2571,3327,56.41%,40.63% 鼻渊舒口服液/胶囊系列,2690,861,1829,67.98%,22.33% 钢结构制作,410,407,2,0.6%,0.03% 钢结构工程施工,10660,8885,1775,16.65%,21.67% 华神科技,000790,收入构成,报告日期,2010-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 兽药及兽用生物疫苗,3468,2367,1101,31.74%,7.13% 生物制药(利卡汀),2083,727,1356,65.09%,8.79% 其他中西成药,1019,856,162,15.94%,1.05% 三七通舒胶囊,8942,3543,5399,60.38%,34.98% 活力苏口服液,1062,304,758,71.35%,4.91% 鼻渊舒口服液/胶囊系,4591,1351,3240,70.58%,20.99% 钢结构制作,2342,2549,-207,-8.84%,-1.34% 钢结构设计,45,35,9,20.9%,0.06% 钢结构工程,24968,21353,3614,14.48%,23.42% 华神科技,000790,收入构成,报告日期,2010-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 兽药及兽用生物疫苗,1414,945,469,33.16%,7.22% 生物制药(利卡汀),840,266,575,68.4%,8.85% 其他中西成药,924,657,268,28.96%,4.12% 三七通舒胶囊,4241,1733,2509,59.15%,38.63% 鼻渊舒口服液/胶囊系列,2430,872,1558,64.13%,24% 钢结构制作,934,909,25,2.65%,0.38% 钢结构设计,47,34,13,28.1%,0.2% 钢结构工程,9099,8021,1078,11.85%,16.6% 华神科技,000790,收入构成,报告日期,2009-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 房地产销售,2134,1835,300,14.03%,2.4% 兽药及兽用生物疫苗,2716,1840,876,32.26%,7.01% 生物制药(利卡汀),1591,536,1055,66.33%,8.44% 其他中西成药,1561,1307,255,16.32%,2.04% 三七通舒胶囊,6010,2002,4009,66.7%,32.05% 活力苏口服液,938,299,639,68.13%,5.11% 鼻渊舒口服液/胶囊系列,4142,1218,2923,70.59%,23.37% 钢结构制作,5081,4428,653,12.85%,5.22% 钢结构设计,139,78,61,43.83%,0.49% 钢结构工程,13452,11715,1737,12.91%,13.89% 华神科技,000790,收入构成,报告日期,2009-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 钢结构制作,2736,2488,248,9.08%,5.12% 钢结构工程,8389,7713,676,8.06%,13.94% 利卡汀,761,236,525,68.97%,10.82% 三七通舒胶囊,2730,863,1867,68.4%,38.52% 鼻渊舒口服液,2209,677,1532,69.34%,31.6% 华神科技,000790,收入构成,报告日期,2008-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 钢结构工程,18773,16555,2218,11.81%,27.73% 利卡汀,1017,384,633,62.25%,7.92% 三七通舒胶囊,4071,1333,2738,67.26%,34.24% 鼻渊舒口服液,3578,1171,2407,67.28%,30.1% 华神科技,000790,收入构成,报告日期,2008-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 钢结构工程,7997,7188,808,10.11%,25.07% 三七通舒胶囊,1823,655,1168,64.09%,36.23% 鼻渊舒口服液,1870,623,1248,66.72%,38.7% 华神科技,000790,收入构成,报告日期,2007-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 新型钢结构建筑工程的承揽,15692,13829,1863,11.87%,34.11% 三七通舒胶囊,2433,996,1437,59.07%,26.32% 鼻渊舒口服液,3363,1203,2160,64.23%,39.56% 华神科技,000790,收入构成,报告日期,2007-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 钢结构工程承揽,6563,5913,650,9.9%,27.04% 三七通舒胶囊,1018,400,618,60.75%,25.74% 鼻渊舒口服液,1783,649,1135,63.64%,47.23% 华神科技,000790,收入构成,报告日期,2006-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 钢结构工程承揽,14934,13118,1815,12.16%,42.33% 鼻渊舒口服液,3709,1236,2473,66.68%,57.67% 华神科技,000790,收入构成,报告日期,2006-09-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 新型钢结构建筑工程承揽,10432,8947,1485,14.23%,46.77% 鼻渊舒口服液,2545,855,1690,66.39%,53.23% 华神科技,000790,收入构成,报告日期,2006-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 钢结构工程承揽,7057,6049,1008,14.28%,39.94% 鼻渊舒口服液,2266,751,1515,66.86%,60.06% 华神科技,000790,收入构成,报告日期,2006-03-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 新型钢结构建筑工程承揽,1913,1570,343,17.94%,38.22% 鼻渊舒口服液,857,302,555,64.77%,61.78% 华神科技,000790,收入构成,报告日期,2005-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 新型钢结构建筑工程的承揽,10557,9224,1334,12.63%,36.06% 鼻渊舒口服液,3632,1267,2365,65.12%,63.94% 华神科技,000790,收入构成,报告日期,2005-09-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 新型钢结构建筑工程承揽,5925,5193,733,12.36%,27.43% 鼻渊舒口服液,2961,1023,1938,65.45%,72.57% 华神科技,000790,收入构成,报告日期,2005-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 钢结构工程承揽,4801,4216,585,12.18%,29.24% 鼻渊舒口服液,2118,704,1415,66.79%,70.76% 华神科技,000790,收入构成,报告日期,2004-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 新型钢结构建筑,12542,10670,1872,14.93%,47.74% 鼻渊舒口服液,4096,2047,2049,50.03%,52.26% 华神科技,000790,收入构成,报告日期,2004-09-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 新型钢结构建筑,7430,6420,1011,13.6%,32.51% 鼻渊舒口服液,3243,1145,2098,64.68%,67.49% 华神科技,000790,收入构成,报告日期,2004-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 钢结构工程承揽,5058,4364,694,13.73%,37.63% 鼻渊舒口服液,2313,1162,1151,49.75%,62.37% 华神科技,000790,收入构成,报告日期,2004-03-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 新型钢结构建筑工程承揽,2691,2232,459,17.05%,47.62% 鼻渊舒口服液,1032,527,505,48.9%,52.38% 华神科技,000790,收入构成,报告日期,2003-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 新型钢结构建筑工程的承揽,8628,7392,1235,14.32%,39.69% 鼻渊舒口服液,3829,1952,1877,49.02%,60.31% 华神科技,000790,收入构成,报告日期,2003-09-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 新型钢结构建筑工程承揽,6003,5007,996,16.59%,34.72% 鼻渊舒口服液,2916,1044,1872,64.2%,65.28% 华神科技,000790,收入构成,报告日期,2003-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 鼻渊舒口服液,1926,980,946,49.14%,100% 华神科技,000790,收入构成,报告日期,2003-03-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 新型钢结构建筑工程承揽,1197,934,264,22.01%,37.32% 鼻渊舒口服液,901,458,443,49.14%,62.68% 华神科技,000790,收入构成,报告日期,2002-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 新型钢结构建筑工程的承揽,7075,5605,1470,20.78%,47.07% 鼻渊舒口服液,3126,1472,1653,52.9%,52.93%